Bladder Cancer Treatment Updates

Even though 75% to 85% of the 83,000 annual US bladder cancer cases are non–muscle invasive bladder cancer (NMIBC), safe and effective treatment options remain limited, and many patients need novel solutions.
Stay up to date on the latest advances in bladder cancer treatment with this brief CME activity. Explore key insights from AUA and ASCO 2025, including new clinical trial data and emerging therapies. Designed for oncologists and the entire multidisciplinary care team, this activity helps you navigate the evolving clinical landscape and apply the most current evidence to practice.

• Explore new options for NMIBC, including FDA-approved salvage therapies for patients unresponsive to BCG
• Learn strategies for side effect management and patient-centered care, even for those ineligible for radical surgery
• Stay ahead with evidence-based insights to support your ability to personalize treatment and improve outcomes

Faculty

Matthew Galsky, MD   Professor of Medicine (Hematology and Medical Oncology)   Director of Genitourinary Medical Oncology   Co-Director of the Center of Excellence for Bladder Cancer Associate Director for Translational Research The Tisch Cancer Institute  Mount Sinai School of Medicine  New York, NY